Successful treatment of lower urinary tract infections with oral fosfomycin: a report of three cases

Silva, Juliana Oliveira da; Yu, Maria Cecília Zorat; Doi, André Mario; Araújo, Maria; Neto, Pedro Aurélio Mathiasi; Furtado, Guilherme Henrique Campos

doi:10.1590/0037-8682-0289-2014

Cited by 4 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is interesting to note that patient 10 had a MIC at 32 mg/L on the initial urine culture, and a controlled MIC at 16 mg/L on the urine culture during relapse, despite exposure to oral FT. The efficacy of fosfomycin despite high MICs has also been described by Oliveira Silva et al with two cases of acute male K. pneumoniae UTI with MICs > 4 mg/L (8 and 128 mg/L) treated from 1 week but with a high dose of 3 g twice daily with good safety [ 19 ].…”

Section: Discussionmentioning

confidence: 79%

“…Only few studies suggested a possible place in this indication [ 5 , 12 , 13 , 14 ]. Recent clinical data support efficacy for the treatment of male UTIs with a clinical cure rate of 50 to 77% and a microbiological eradication rate of more than 50% in male UTIs with E. coli [ 2 , 16 , 17 , 18 , 19 ]. Pharmacokinetic data show intra-prostatic diffusion at therapeutic rates with a prostate/blood ratio of 60–70% and an intra-prostatic therapeutic concentration 17 h after administration [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales

Bouiller

Zayet²,

Lalloz

et al. 2022

Antibiotics

View full text Add to dashboard Cite

Background: Antimicrobial drugs to treat male urinary tract infection (UTI) with multidrug-resistant Enterobacterales are limited. We studied oral fosfomycin-trometamol (FT) in this situation. The objective was to assess the clinical cure rate in patients presenting UTIs treated with oral FT. Methods: We conducted a single-center observational retrospective study from January 2017 to August 2018. The primary endpoint was clinical cure; and the secondary endpoints were incidence of recurrences, oral FT safety, and microbiological cure. Results: Sixteen male patients were included, presenting 21 UTI episodes. Fourteen patients (88%) have at least one underlying urologic disorder. We described 4 episodes of acute UTI and 17 episodes of chronic bacterial prostatitis (CBP). Sixteen out of twenty-one Enterobacterales were extended spectrum beta-lactamase (ESBL)-producers and all the patients presented a resistance to fluoroquinolones and trimethoprim/sulfamethoxazole. In acute UTI, the regimen was a daily dose of oral FT for a mean duration of 2.5 weeks (+/−7.0 days). Clinical and microbiological recovery was achieved in all patients, with no recurrence after 5.3 months follow-up on average (+/−10.4 days). In CBP, the regimen was one oral dose of fosfomycin every 24–48 h, for a mean duration of 5.5 weeks/UTI episodes (+/−15.3 days). Clinical and microbiological recovery was found in 16/17 cases. Seven of the twelve patients with CBP had relapsed and 3/12 had had a new episode of infection after an average follow-up of 5.8 months. Only 6/21 of patients presented minor or moderate adverse effects, such as digestive disorders. Conclusions: FT could be an alternative option to carbapenems in the treatment of multidrug-resistant Enterobacterales infections for male UTIs.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales

Bouiller

Zayet²,

Lalloz

et al. 2022

Antibiotics

View full text Add to dashboard Cite

show abstract

“…En el estado de San Pablo, el Hospital Municipal Dr. José de Carvalho Florence, de la ciudad de São José dos Campos, 45 y el Hospital de las Clínicas de la ciudad de Ribeirão Preto 9,23,[46][47][48][49][50][51][52][53][54] describen infecciones por enterobacterias productoras de la carbapenemasa KPC. En la ciudad de San Pablo los siguientes hospitales fueron identificados: el Hospital del Corazón y el Hospital San Pablo, 47 el Hospital de las Clínicas, 9,45 el Instituto del Cáncer del Estado de San Pablo, 45,48 el Hospital Dante Pazzanese de Cardiología, [49][50][51] el Hospital Heliópolis, 52 el Hospital Brigadeiro 53 y el Hospital M'boi Mirim. 54 En Brasil, así como en muchos otros países, no existe un programa de vigilancia de todas las infecciones causadas por bacterias multi-resistentes.…”

Section: Discussionunclassified

Infección por Klebsiella pneumoniae Productora de Carbapenemasa en Receptores de Transplante Renal

Júnior

Foresto

Viana

et al. 2022

BJT

View full text Add to dashboard Cite

Resumen: Existe una tendencia de aumento del número de casos de infección por bacterias multi-resistentes, teniendo en vista el uso indiscriminado y, a veces, excesivo de antibióticos de amplio espectro en el ambiente hospitalario. Esas infecciones generaron un gran impacto, principalmente en pacientes inmunosuprimidos sometidos al transplante de órganos sólidos. Datos nacionales revelaron un aumento significativo de las tasas de infecciones por bacterias multi-resistentes. El presente estudio tuvo como objetivo evaluar la incidencia y demografía de las infecciones relacionadas a la asistencia a la salud por Klebsiella pneumoniae productora de carbapenemasa (KPC). Este es un estudio observacional, retrospectivo, descriptivo, realizado en centro único (Hospital del Riñón) con evaluación de los resultados de receptores de transplante renal con infección por KPC entre noviembre del 2009 y diciembre del 2015. En nuestro centro, infección de corriente sanguínea por KPC tuvo mayor prevalencia, seguida de infección del aparato urinario. La mortalidad general en 30 días fue del 36%, semejante a la encontrada en la literatura internacional. La infección por bacterias multi-resistentes es una condición clínica grave en pacientes transplantados y constituye un desafío terapéutico.

show abstract

“…In the state of São Paulo, the Hospital Municipal Dr. José de Carvalho Florence, of the city of São José dos Campos, 45 and the Hospital das Clínicas of the city of Ribeirão Preto 9,23,[46][47][48][49][50][51][52][53][54] describe infections by enterobacteria producing the KPC carbapenemase. In the city of São Paulo, the following hospitals were identified: the Heart Hospital and the São Paulo Hospital, 47 the Clinics Hospital, 9,45 the Cancer Institute of the State of São Paulo, 45,48 the Dante Pazzanese Cardiology Hospital, [49][50][51] the Heliópolis Hospital, 52 the Brigadeiro Hospital 53 and the M'boi Mirim Hospital. 54 In Brazil, as in many other countries, there is no surveillance program for all infections caused by multidrug-resistant bacteria.…”

Section: Discussionmentioning

confidence: 99%

Infection by Carbapenemase-Producing Klebsiella pneumoniae in Renal Transplant Recipients

Júnior

Foresto

Viana

et al. 2022

BJT

View full text Add to dashboard Cite

There is a tendency to increase the number of cases of infection by multidrug-resistant bacteria, in view of the indiscriminate and sometimes excessive use of broad-spectrum antibiotics in the hospital environment. These infections have generated great impact, especially in immunosuppressed patients undergoing solid organ transplantation. National data revealed a significant increase in the rates of infections by multidrug-resistant bacteria. The present study aimed to evaluate the incidence and demographics of health care-related infections by carbapenemase-producing K. pneumoniae (KPC). This is an observational, retrospective, descriptive study conducted at a single center (Kidney Hospital) with evaluation of the outcomes of kidney transplant recipients with KPC infection between November 2009 and December 2015. In our center, KPC bloodstream infection had the highest prevalence, followed by urinary tract infection. The overall 30-day mortality was 36%, similar to that found in the international literature. Infection with multidrug-resistant bacteria is a serious clinical condition in transplant patients and poses a therapeutic challenge.

show abstract

Successful treatment of lower urinary tract infections with oral fosfomycin: a report of three cases

Cited by 4 publications

References 11 publications

Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales

Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales

Infección por Klebsiella pneumoniae Productora de Carbapenemasa en Receptores de Transplante Renal

Infection by Carbapenemase-Producing Klebsiella pneumoniae in Renal Transplant Recipients

Contact Info

Product

Resources

About